Normal view MARC view ISBD view

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Dahan, Rony

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. [electronic resource] - Cancer cell 06 2016 - 820-831 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural

ISSN: 1878-3686

Standard No.: 10.1016/j.ccell.2016.05.001 doi

Subjects--Topical Terms:
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
CD40 Antigens--agonists
Cell Line, Tumor
Humans
Immunotherapy
Mice
Neoplasms--drug therapy
Receptors, IgG--immunology
Xenograft Model Antitumor Assays

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)